Based on the L&G Pharma Breakthrough UCITS ETF stock forecast from 0 analysts, the average analyst target price for L&G Pharma Breakthrough UCITS ETF is not available over the next 12 months. L&G Pharma Breakthrough UCITS ETF’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of L&G Pharma Breakthrough UCITS ETF is Very Bearish, which is based on 0 positive signals and 3 negative signals. At the last closing, L&G Pharma Breakthrough UCITS ETF’s stock price was EUR 9.53. L&G Pharma Breakthrough UCITS ETF’s stock price has changed by -3.21% over the past week, -4.34% over the past month and +1.58% over the last year.
No recent analyst target price found for L&G Pharma Breakthrough UCITS ETF
No recent average analyst rating found for L&G Pharma Breakthrough UCITS ETF
Company Overview L&G Pharma Breakthrough UCITS ETF
Stock Target Advisor's fundamental analysis for L&G Pharma Breakthrough UCITS ETF's stock is Very Bearish.
ETLI:XETRA stock's dividend yield is 0.94%.
Our analysis grades ETLI:XETRA stock's dividend yield at F. This means that ETLI:XETRA stock's dividend yield is above 6% of the stocks in the Others sector in the XETRA exchange.
Based on this ETLI:XETRA may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on ETLI:XETRA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on ETLI:XETRA's stock to indicate if its overvalued.
The last closing price of ETLI:XETRA's stock was EUR 9.53.
The most recent market capitalization for ETLI:XETRA is EUR 0.02B.
Unfortunately we do not have enough analyst data on ETLI:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains L&G Pharma Breakthrough UCITS ETF's stock.
Sorry, we do not have any data on the number of employees for L&G Pharma Breakthrough UCITS ETF.
Sorry we do not have any infomation available on L&G Pharma Breakthrough UCITS ETF's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Stock Target Advisor's fundamental analysis for L&G Pharma Breakthrough UCITS ETF's stock is Very Bearish.
ETLI:XETRA stock's dividend yield is 0.94%.
Our analysis grades ETLI:XETRA stock's dividend yield at F. This means that ETLI:XETRA stock's dividend yield is above 6% of the stocks in the Others sector in the XETRA exchange.
Based on this ETLI:XETRA may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on ETLI:XETRA's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on ETLI:XETRA's stock to indicate if its overvalued.
The last closing price of ETLI:XETRA's stock was EUR 9.53.
The most recent market capitalization for ETLI:XETRA is EUR 0.02B.
Unfortunately we do not have enough analyst data on ETLI:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains L&G Pharma Breakthrough UCITS ETF's stock.
Sorry, we do not have any data on the number of employees for L&G Pharma Breakthrough UCITS ETF.
Sorry we do not have any infomation available on L&G Pharma Breakthrough UCITS ETF's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ETLI:XETRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
